Pyridoxal

Summary

Pyridoxal (CHEMBL102970) is a phase-3 clinical-stage small-molecule cofactor.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 2
• Chemistry: 167.16 Da · C8H9NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL102970
Name	Pyridoxal
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	1050
ChEBI	CHEBI:17310
Molecular formula	C8H9NO3
Molecular weight	167.16
InChIKey	RADKZDMFGJYCBB-UHFFFAOYSA-N

SMILES: CC1=NC=C(C(=C1O)C=O)CO

IUPAC name: 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carbaldehyde

ChEBI definition: A pyridinecarbaldehyde that is pyridine-4-carbaldehyde bearing methyl, hydroxy and hydroxymethyl substituents at positions 2, 3 and 5 respectively. The 4-carboxyaldehyde form of vitamin B6, it is converted into pyridoxal phosphate, a coenzyme for the synthesis of amino acids, neurotransmitters, sphingolipids and aminolevulinic acid.

Pharmacological roles (ChEBI): cofactor.

Other ChEBI roles (chemical / environmental): human metabolite, Saccharomyces cerevisiae metabolite, Escherichia coli metabolite, mouse metabolite.

Also known as: Piridoxal, Pyridoxal, Pyridoxaldehyde, SID26754377, SID29215199, SID29215200, SID170466865, PYRIDOXAL, pyridoxal

Parent form; salt/anhydrous children: CHEMBL543846

Patent coverage: 7,388 distinct patent families (24,358 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Lysine-specific demethylase 4E, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Menin/Histone-lysine N-methyltransferase MLL, Aldehyde oxidase, Aldehyde dehydrogenase 1A1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06234501	Not specified	RECRUITING	Testing the Efficacy of 100mg Vitamin-B6 Daily for Sensory Reactivity in Autism
NCT00933998	Not specified	COMPLETED	Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).